Even though there have been major scientific developments in the fields of pharmaceutical analytical chemistry, manufacturing science, and regulatory science over the last twenty years, the incorporation of validated innovations into routine industrial practice remains slow, irregular, and incomplete. Although Quality by Design (QbD), Process Analytical Technology (PAT), continuous manufacturing (CM), Real-Time Release Testing (RTRT), and artificial intelligence (AI) are backed by strong scientific bases and have clear regulatory routes, their adoption differs greatly from product to product, facility to facility, and region to region. This structured narrative review uses implementation science, a field that systematically examines methods for integrating evidence into everyday practice, to examine innovations in pharmaceutical analytical and manufacturing processes. The review brings together the regulatory environments in the United States (21 CFR Parts 210/211, the FDA Emerging Technology Program, Quality Management Maturity), in the European Union (EudraLex Volume 4, Annex 1 on sterile manufacturing, the reform of EU pharmaceutical legislation), and in international frameworks (ICH Q8–Q14, M7, Q3D; WHO GMP; PIC/S Annex 11). Based on the Consolidated Framework for Implementation Research (CFIR), the RE-AIM evaluation model, and the Expert Recommendations for Implementing Change (ERIC) compilation, the review links implementation strategies to the various domains of pharmaceutical innovation. It examines FDA drug shortage reporting, analyzes 1,766 FDA Warning Letters (from 2016 to 2023), examines biosimilar uptake, and reviews regulatory submissions for continuous manufacturing. The review concludes with an implementation science framework tailored to the pharmaceutical industry, an example KPI dashboard, and 12 evidence-based recommendations. The main point is that, for a number of well-established innovations, the ability to implement them is now the main barrier to their routine adoption.